Adding weekly paclitaxel to treat advanced endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding a weekly dose of the chemotherapy drug paclitaxel to standard treatment helps women with advanced or recurrent endometrial cancer. It is for patients whose cancer has returned or not responded to prior therapy, including at least one platinum-based chemotherapy and an immune checkpoint inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced, recurrent, or persistent endometrial cancer (a type of cancer in the lining of the uterus) that has not responded to treatment.
- You have received at least one platinum-based chemotherapy for advanced or recurrent cancer, and no more than 5 prior lines of therapy overall.
- You have a tissue sample from before treatment (archival tissue) available.
- Your cancer can be measured on a CT scan (for the main part of the study) or you have accessible tumors (for the safety lead-in).
- You have a performance status of 0 to 2 (meaning you are up and active or able to care for yourself but may not be able to do heavy work).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This study uses a tumor “biomarker” test to guide treatment in people with endometrial cancer (and sometimes epithelial ovarian cancer). It tests whether tailoring weekly chemotherapy (paclitaxel) based on biomarker levels can help patients, especially when the cancer has come back or is advanced.
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests whether adding BMX-001 to the chemotherapy drug paclitaxel can help people with advanced ovarian or endometrial cancer that has come back or spread. It aims to see if this combination is safe and effective.
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.